SCHEMBL9265347

SCHEMBL9265347

Cc1ccc(Cl)c(Nc2ccccc2C(N)=O)c1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLCN2 P51788 2/20 1.00
PTGS2 P35354 13/20 0.77
MEN1 O00255 2/20 0.77
MAPK1 P28482 2/20 0.77
KMT2A Q03164 2/20 0.77
METTL3 Q86U44 2/20 0.77
TTR P02766 2/20 0.77
AKR1B10 O60218 1/20 0.77
ABCB11 O95342 1/20 0.77
ADORA3 P0DMS8 1/20 0.77
CHRM1 P11229 1/20 0.77
FABP2 P12104 1/20 0.77
RXRA P19793 1/20 0.77
TBXA2R P21731 1/20 0.77
NR4A1 P22736 1/20 0.77
PTGS1 P23219 1/20 0.77
PDE4A P27815 1/20 0.77
AKR1C3 P42330 1/20 0.77
NR4A2 P43354 1/20 0.77
AKR1C2 P52895 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9264265 1.00 CLCN2 (1.00) CLCN2PTGS2MEN1MAPK1KMT2A
SCHEMBL26733371 0.89 CLCN2 (0.80) CLCN2PTGS2MEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL106 0.87 PTGS2 (1.00) CLCN2PTGS2MEN1MAPK1KMT2A
SCHEMBL11013086 0.87 PTGS2 (0.79) CLCN2PTGS2MEN1MAPK1KMT2A
SCHEMBL7346365 0.87 PTGS2 (0.79) CLCN2PTGS2MEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL29373906 0.87 PTGS2 (1.00) CLCN2PTGS2MEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL11543781 0.87 PTGS2 (1.00) CLCN2PTGS2MEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL29379636 0.87 PTGS2 (1.00) CLCN2PTGS2MEN1MAPK1KMT2A
SCHEMBL9268418 0.86 PTGS2 (0.77) CLCN2PTGS2MEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL17200177 0.86 PTGS2 (0.97) CLCN2PTGS2MEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4272761-A2 COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS Medicon Pharmaceuticals, Inc. (US) 2023-11-08 EP disclosed
US-11173137-B2 Compositions and methods to modulate chloride ion channel activity THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-11-16 US disclosed
US-5462952-A Have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase WARNER-LAMBERT COMPANY (US) 1995-10-31 US disclosed
EP-0401857-A2 Fenamate 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as antiinflammatory agents WARNER-LAMBERT COMPANY (US) 1990-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11173137-B2 Compositions and methods to modulate chloride ion channel activity CLCN2, CLIC1, CLIC4 CLCN2 1/4885PTGS2 2251/4885MEN1 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.